AI Analysis
AI-generated analysis. Always verify with the original filing.
FY2025 saw Cadrenal Therapeutics post wider operating and net losses alongside increased cash burn, with near-term capital needed to fund planned operations.
Key Takeaways
1GAAP operating loss widened 22.8% YoY to $13.5M for FY2025, driven by increased net operating losses and capitalized research costs during the year.
2GAAP net loss expanded 24.3% YoY to $13.2M for FY2025, consistent with elevated investment in research and operating activities.
3Diluted GAAP EPS improved 23.9% YoY to -$6.64 for FY2025, compared to a loss of -$8.73 per share in FY2024.
4Cash used in operating activities totaled $12.6M for FY2025, up from $7.4M in cash used for operating activities in FY2024.
5The company expects to raise additional capital to fund clinical trials, commercialization, R&D, and public company operating costs.